Abbott shared today that Bowling Green, Ohio, will be the location for its new specialty and metabolic powder nutritional products manufacturing facility. This state-of-the-art plant will bring additional capacity to the U.S. supply of these important formulas, some of which serve as the sole source of nutrition for people with extreme allergies to most food products and other dietary and metabolic conditions. Abbott plans to invest more than $500 million in the facility and create 450 permanent new jobs in the northwest Ohio region, contingent on approvals from state and local officials. Groundbreaking is expected to begin in 2023 and construction is expected to be complete in 2026, subject to necessary approvals. Abbott expects to start commercial production of products in 2027. Upon completion of the new facility, Abbott plans to continue operating its Sturgis, Mich., plant, including producing specialty and metabolic powder formulas to help maintain supply of these critical products.